William J. Sandborn

William Sandborn is currently the Chief Strategy Officer at Mirador Therapeutics and a Member of the Board of Directors at Prometheus Laboratories Inc. With a background in medicine and experience in various leadership roles within the biosciences industry, William has a wealth of knowledge and expertise. Sandborn has co-founded multiple companies and played key roles in their acquisitions, including the $10.8 billion acquisition of Prometheus Biosciences by Merck in 2023. Their career has been marked by a commitment to advancing gastroenterology and hepatology, with previous roles such as Distinguished Professor of Medicine at the University of California, San Diego and Professor of Medicine at the Mayo Clinic.